Aditxt's filings show a precommercial health-innovation platform with immune, diagnostic, infectious-disease, women's-health, and proteomics ambitions, but the source-backed decision point is Nasdaq survival, cash, dilution, and whether any program can outrun the capital structure.
References
Sources used in this report
SEC APISEC company tickers exchange dataset2026-05-14 · Ticker, exchange, company name, and CIK confirmation.SEC APISEC submissions JSON2026-05-14 · Issuer identity, SIC, fiscal year end, current address, and filing sequence.SEC APISEC companyfacts JSON2026-05-14 · Financial statement and balance sheet cross-checks.SEC annual filingFY2025 Form 10-K2026-03-31 · Business model, subsidiaries, liquidity, going concern, reverse-split history, risks, audited financials, and legal proceedings.SEC quarterly filingQ3 2025 Form 10-Q2025-11-18 · Latest interim financial baseline before FY2025 filing and post-year 8-Ks.SEC proxy filing2026 definitive proxy statement2026-04-03 · Governance, executive officers, director nominees, stock ownership, and reverse-split authority proposal.SEC current report2026 annual meeting results Form 8-K2026-05-01 · Annual meeting voting results and governance update.SEC current reportNasdaq bid-price delisting determination Form 8-K2026-05-08 · Bid-price delisting determination and planned hearing appeal.SEC current reportApril 2026 senior unsecured note Form 8-K2026-04-14 · Post-year note financing terms and maturity.SEC current reportIgnite Proteomics acquisition and March notes Form 8-K2026-03-13 · Ignite acquisition, Series A-2 preferred consideration, and March note financing.